COR Stock Cencora, Inc.
US · NYSELast in our picks 2026-10-07 — not in the current list; analysis below is from that screen
Specialty distribution scale, M&A catalysts, and analyst support make it attractive now.
Future value: $369.25 (+16.71%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Upgraded to Overweight on specialty pharma strength and acquisition catalyst.
- ▾Below 50-day MA (-0.48%)
Is COR a buy right now?
Trend: COR is trading above the 50-day average (+2.37%), RSI 43 — neutral momentum, with a 3-month return of +3.26%.
Valuation & quality: Cencora, Inc. trades on a trailing P/E of 24.5, forward P/E 16.7, PEG 0.69, price-to-book 20.64; fundamentals show net margin 0.8%, return on equity 96.9%, revenue growth 5.1% year on year.
Analyst consensus: 12 analysts have a mean 12-month price target of $369.08 (+11.8% vs the last close; range $330.00 – $400.00), consensus rating “buy”.
Income: trailing dividend yield 0.73%.
Our screen: BUY (score 2) — Specialty distribution scale, M&A catalysts, and analyst support make it attractive now.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -15.60% | -2.00% | -12.50% | +5.10% | +10.00% | +3.90% | -7.20% | +9.90% |
Fundamentals
Analyst price target
Technical signals
About Cencora, Inc.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S.
Sector: Healthcare · Industry: Medical Distribution · United States · 47,000 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.